This article is more than 5 years old. Information may no longer be current.
VIDEO: Updated KEYNOTE-024 results raise question in sequencing of lung cancer treatments
CHICAGO — Hossein Borghaei, DO, chief of the division of thoracic medical oncology at Fox Chase Cancer Center, discusses the updated KEYNOTE-024 data and how the results could have implications for patients with non–small cell lung cancer who present with a PD-L1 tumor progression score of less than 50%.
In this video, Borghaei highlights part of the results that demonstrated that patients who did progress after pembrolizumab (Keytruda, Merck) and received subsequent therapy appeared to have better responses than what is seen in patients who receive chemotherapy followed by immunotherapy.
In addition, Borghaei raises a question about the sequencing of treatments in this patient population.
“Is it better to start with an [immunotherapy] agent followed by chemotherapy or is it better to start with chemotherapy followed by [immunotherapy]?,” he said.
Reference:
Brahmer JR, et al. Abstract 9000. Presented at: ASCO Annual Meeting; June 2-6, 2017; Chicago.
Disclosure: Borghaei reports serving on an advisory board for Merck.